This product can inhibit viral DNA and RNA polymerase, thereby inhibiting viral reproduction. On human embryonic kidney cells, 1% concentration has a significant inhibitory effect on DNA viruses (adenovirus, herpes virus) and RNA viruses (echovirus), and has an inhibitory effect on all stages of the viral proliferation cycle. It has no direct effect on free viral particles.

Anti-myocardial ischemia, improve hemodynamics, improve blood rheology, and alleviate experimental liver damage

Anti-myocardial ischemia, improve hemodynamics, improve blood rheology, and alleviate experimental liver damage

1. Anti-myocardial ischemia: Intravenous injection of 0.8, 1.6, and 3.2 g/kg of this product can reduce the scope of myocardial infarction in dogs with acute myocardial ischemia caused by ligation of the left anterior descending coronary artery, slow down the acceleration of heart rate caused by ischemia, reduce the release of CK, LDH, and MDA in serum, and enhance SOD activity. 2. Effect on hemodynamics: Intravenous injection of 0.26, 0.78, and 2.34 g/kg of this product can significantly increase the coronary flow and cardiac output of anesthetized dogs, reduce femoral artery systolic pressure (SAP), diastolic pressure (DAP), and mean arterial pressure (MAP). 3. Improve blood rheology: Intravenous injection of 4 g/kg of this product can significantly reduce the whole blood viscosity, hematocrit, and platelet aggregation of rats with blood stasis syndrome caused by intravenous injection of glucose saline, and increase the maximum deformation coefficient of red blood cells. 4. Other effects Oral administration of 0.4 and 0.8 g/kg of this product can reduce experimental liver damage in mice caused by galactosamine, reduce the levels of plasma and liver homogenate peroxide (LPO) and malondialdehyde (MDA), and reduce the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

1. Anti-myocardial ischemia: Intravenous injection of 0.8, 1.6, and 3.2 g/kg of this product can reduce the scope of myocardial infarction in dogs with acute myocardial ischemia caused by ligation of the left anterior descending coronary artery, slow down the acceleration of heart rate caused by ischemia, reduce the release of CK, LDH, and MDA in serum, and enhance SOD activity. 2. Effect on hemodynamics: Intravenous injection of 0.26, 0.78, and 2.34 g/kg of this product can significantly increase the coronary flow and cardiac output of anesthetized dogs, reduce femoral artery systolic pressure (SAP), diastolic pressure (DAP), and mean arterial pressure (MAP). 3. Improve blood rheology: Intravenous injection of 4 g/kg of this product can significantly reduce the whole blood viscosity, hematocrit, and platelet aggregation of rats with blood stasis syndrome caused by intravenous injection of glucose saline, and increase the maximum deformation coefficient of red blood cells. 4. Other effects Oral administration of 0.4 and 0.8 g/kg of this product can reduce experimental liver damage in mice caused by galactosamine, reduce the levels of plasma and liver homogenate peroxide (LPO) and malondialdehyde (MDA), and reduce the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

Zolmitriptan is a selective 5-HTIB/ID receptor agonist. It stimulates 5-HTIB/ID receptors on intracranial blood vessels (including arteriovenous anastomosis) and sympathetic nerves of the trigeminal nervous system, causing intracranial vasoconstriction and inhibiting the release of pro-inflammatory neuropeptides. It is used to treat migraine with or without aura in adults.